By adminPosted on March 24, 2025Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a mid-stage study. Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech Views: 3 Post navigation AstraZeneca Makes Potential $10B+ China Commitment Despite Political PressureTempero Raises $70M to Fight Substance Use Disorders
